Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 21, 2023
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
Edward Nash Maintained (AKRO) at Strong Buy with Increased Target to $58 on, Mar 21st, 2023
Edward Nash of Canaccord Genuity, Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Increased Target from $50 to $58 on, Mar 21st, 2023.
Edward has made no other calls on AKRO in the last 4 months.
There are 2 other peers that have a rating on AKRO. Out of the 2 peers that are also analyzing AKRO, 0 agree with Edward's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Edward
- Ed Arce of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $64 on, Monday, March 20th, 2023
- Michael Ulz of "Morgan Stanley" Upgraded from Hold to Buy and Held Target at $65 on, Friday, January 27th, 2023
